Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$145.13 USD

145.13
85,100,213

+11.81 (8.86%)

Updated Aug 21, 2026 03:59 PM ET

After-Market: $145.37 +0.24 (0.17%) 4:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.94%
2Buy18.22%
3Hold10.27%
4Sell5.79%
5Strong Sell3.20%
S&P50011.55%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (160 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CureVac Begins Phase IIa Study on Coronavirus Vaccine Candidate

by Zacks Equity Research

CureVac (CVAC) doses the first patient in a phase IIa study on its COVID-19 vaccine candidate CVnCoV. Shares rise in after-hours trading following this development.

Neena Mishra headshot

ETFs To Play The IPO Boom

by Neena Mishra

These ETFs provide diversified exposure to hottest IPOs

Sweta Killa headshot

5 Biggest Wall Street Stories of the First Nine Months of 2020

by Sweta Killa

The pandemic has accelerated the digital shift, thus driving the e-commerce boom.

John Blank headshot

5 Vaccine Stocks to Buy Now

by John Blank

The COVID-19 sponsor companies are either in the Zacks Large Cap Pharma industry, or in Zacks Biomedical and Genetics industry.

Zacks Equity Research

Moderna (MRNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $70.55 in the latest trading session, marking a +1.55% move from the prior day.

Zacks Equity Research

Endo Up on COVID-19 Vaccine Manufacturing Deal with Novavax

by Zacks Equity Research

Endo (ENDP) and Novavax enter a manufacturing agreement for the latter's COVID-19 vaccine candidate, NVX-CoV2373.

Zacks Equity Research

Novavax Begins Phase III Study on Coronavirus Vaccine in the UK

by Zacks Equity Research

Novavax (NVAX) starts a phase III efficacy study on its COVID-19 vaccine candidate NVX-CoV2373 in the United Kingdom. Stock rises in after-hours trading.

Kinjel Shah headshot

4 Coronavirus Vaccine Makers Now in Phase III as J&J Begins Study

by Kinjel Shah

COVID-19 vaccine candidates of four companies - J&J, Pfizer/BioNTech, AstraZeneca/Oxford University and Moderna - are now in late-stage development.

Zacks Equity Research

The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX

by Zacks Equity Research

The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX

Kinjel Shah headshot

4 Biotechs That Have More Than Doubled Thanks to Coronavirus

by Kinjel Shah

Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.